In the dynamic realm of molecular biology, the quest for enhancing diagnostic tools and therapeutic approaches is an ever-evolving journey. One significant breakthrough in this pursuit is the development of the Neomer library, an innovative platform that allows the utilization of identical sequences across various targets. This breakthrough has propelled researchers to delve into a comprehensive characterization of structures within the Neomer library, paving the way for a profound understanding and manipulation of aptamers.
The Neomer Library and Aptamer Structures:
The Neomer library’s groundbreaking feature lies in its ability to deploy the same starting naïve sequences across different targets. This unique characteristic has motivated NeoVentures to invest significant efforts into characterizing the structures within the library comprehensively. The exhaustive endeavor has now yielded a wealth of knowledge, positioning us to delve deeper into the intricacies of these structures immediately after the selection process.
Similar to antibodies, aptamers derive their functionality from the intricate secondary structures they form. In the case of antibodies, these structures are dictated by the sequence and identity of amino acids in the hypervariable regions. Aptamers, on the other hand, rely on the sequence and identity of nucleotides in their hypervariable regions. The detailed understanding of these structures within the Neomer library has set the stage for a transformative approach to aptamer design and improvement.
Building a Knowledge Base for Strategic Design:
Armed with a comprehensive knowledge base of all possible structures within the Neomer library, we can now assess the nature of structures bound by any given target. The meta-analysis capabilities across this expansive database enable us to formulate hypotheses about ideal structures and strategically design them. This in-silico approach to aptamer improvement mirrors the evolutionary principles found in nature.
Emulating Nature’s Strategy:
Nature has perfected the immune system’s ability to screen foreign entities using a relatively small repertoire of naïve antibodies. The selected antibodies undergo recombination to evolve and produce structures with higher binding affinity. Similarly, the Neomer library, with its closed sequence design, enables an in-silico approach to immune tolerance. By defining all structures within the library, we have introduced a parallel in-silico approach to aptamer enhancement, following nature’s time-tested strategy.
Partnering for the Future:
The implications of these advancements extend beyond the laboratory, as more diagnostic companies join forces to pioneer the next wave of applications in healthcare. Collaborations with these forward-thinking entities are crucial for translating research breakthroughs into real-world solutions.
We invite you to explore the possibilities and join the revolution in diagnostic applications. Contact us for a free consultation, where we aim to understand your vision and collaborate to turn it into reality. Together, we can shape the future of molecular diagnostics and therapeutic interventions.
Dr. Gregory Penner academic training was a blend of very practical plant breeding theory combined with molecular biology. He has used this blend of biology and mathematics to first develop and lead a cereal biotechnology research team with the government of Canada and subsequently as a global research leader with Monsanto Inc. He has been a thought leader in aptamer development globally for the last twenty years as CEO and President of NeoVentures. He has led this company to financial stability without outside investment with an integrated approach to aptamer discovery and commercialization. In 2015, he co- founded a second company, NeoNeuro in Paris France, focused on an innovative approach to identify Aptamarkers for complex diseases.
Connect with Dr. Penner on LinkedIn or for company updates, follow NeoVentures.
English 
French 
Spanish